Richard Tajak - NantKwest Interim CFO

CFO

Mr. Richard J. Tajak serves as a Chief Financial Officer of the Company. Richard Tajak has served as our Chief Financial Officer since January 2016. Mr. Tajak has served as Chief Financial Officer of NantPharma, LLC, a specialty pharmaceutical company and whollyowned subsidiary of NantWorks, LLC, since January 2014 and as Chief Operating Officer since June 2014. Prior to that, from July 2011 to December 2013, Mr. Tajak served as Chief Financial Officer of NantWorks, LLC. Prior to NantWorks, LLC, Mr. Tajak served as Executive Vice President and Chief Financial Officer of APP Pharmaceuticals, Inc., a 1 billion generic pharmaceutical company, from April 2008 to June 2011 after having joined the company as Senior Vice President, Finance in March 2008. Prior to that, he was Senior Vice President, Finance for the 1.5 billion North American division of Astellas Pharmaceuticals, Inc. His earlier career was at Fujisawa HealthcareUSA and Lyphomed, Inc., where he had increasing levels of responsibility in the areas of accounting, finance, SEC reporting, audit, tax, and corporate operations since 2016.
Age 64
Tenure 8 years
Phone858 633-0300
Webwww.nantkwest.com
Tajak holds a Bachelor’s degree in Finance and a Masters of Business Administration from the University of Notre Dame, and is a Certified Public Accountant.

NantKwest Management Efficiency

The company has Return on Asset (ROA) of (38.83) % which means that for every 100 dollars spent on asset, it generated a loss of $38.83. This is way below average. Likewise, it shows a return on total equity (ROE) of (77.61) %, which implies that it produced no returns to current stockholders. NantKwest's management efficiency ratios could be used to measure how well NantKwest manages its routine affairs as well as how well it operates its assets and liabilities.
The company reports 15.31 M of total liabilities with total debt to equity ratio (D/E) of 0.13, which may suggest the company is not taking enough advantage from financial leverage. NantKwest has a current ratio of 3.0, indicating that it is in good position to pay out its debt commitments in time. Debt can assist NantKwest until it has trouble settling it off, either with new capital or with free cash flow. So, NantKwest's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like NantKwest sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for NantKwest to invest in growth at high rates of return. When we think about NantKwest's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 3 records

CFO Age

Andrew DavisEmerson Radio
46
William RobertsonVisteon Corp
57
Jeffrey StafeilVisteon Corp
44
NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California. Nantkwest Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. NantKwest (NK) is traded on NASDAQ Exchange in USA and employs 160 people.

Management Performance

NantKwest Leadership Team

Elected by the shareholders, the NantKwest's board of directors comprises two types of representatives: NantKwest inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NantKwest. The board's role is to monitor NantKwest's management team and ensure that shareholders' interests are well served. NantKwest's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NantKwest's outside directors are responsible for providing unbiased perspectives on the board's policies.
Cheryl Cohen, Director
Richard Kusserow, Independent Director
Angela Wilson, CFO
Sonja Nelson, Chief Accounting Officer
Barry Simon, President CEO, Board Member
Michael Blaszyk, Independent Director
Frederick Driscoll, Independent Director
John Thomas, Independent Director
Robert Rosen, Director
Richard Tajak, Interim CFO
Patrick SoonShiong, Chairman of the Board, CEO
Henry Ji, Director
John Potts, Independent Director
Steven Gorlin, Vice Chairman of the Board

NantKwest Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NantKwest a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards NantKwest in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, NantKwest's short interest history, or implied volatility extrapolated from NantKwest options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Other Consideration for investing in NantKwest Stock

If you are still planning to invest in NantKwest check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NantKwest's history and understand the potential risks before investing.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
CEOs Directory
Screen CEOs from public companies around the world
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Content Syndication
Quickly integrate customizable finance content to your own investment portal